Please connect with our team. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that Ferdinand Massari, M.D., has been appointed Chief Medical Officer. In parallel with the urgent demand for robust algorithms, deep learning has succeeded in a variety of fields such as vision, speech, and text processing. The company hasn’t reported full-year 2018 revenue yet (it is scheduled for April 25), but its most recent four quarters indicated 18% growth from the $311.607 million reported in 2017. Deep Genomics raises $40 million Series B for AI drug discovery platform Toronto-based AI therapeutics startup, Deep Genomics, has closed a $40 million Series B. Genomics is the study of all of a person's genes (the genome), including interactions of those genes with each other and with the person's environment. Our facilities span experimental biology and computational analysis. Choose from 5-inner door upright freezers (Revco) or 4-inner door upright (TSX, Forma). Following the success of previous ROTH conferences with 500+ companies and 5,000+ attendees attending annually, this year's event will take place in a virtual format. Toronto is the fastest growing tech hub in North America and widely recognized as one of the most livable cities in the world. ALL RIGHTS RESERVED. “Deep Genomics has pioneered a better way to systematically discover new therapies with a much higher success rate than traditional pharma methods. Deep Genomics in September identified its first therapeutic candidate, the oligonucleotide therapy DG12P1, which is designed to treat Wilson disease in patients who possess Met645Arg, a mutation shown to lead to the loss of function of the ATP7B copper-binding protein. From TechCrunch. Recent news which mentions Deep Genomics. Wilson disease affects approximately one in every 30,000 people worldwide and, if left untreated, can cause life-threatening organ damage. Deep Genomics is proud to announce that Peter Barton Hutt, Senior Counsel at Deep Genomics Raises $40 Million in Series B Financing, – Led by Future Ventures, includes top healthcare and technology funds Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures The proceeds from this financing will be used to develop new treatments for rare genetic diseases, and to expand the company’s proprietary AI discovery platform to support the discovery and development of novel therapies for more common disorders. In 2018, our proprietary AI Workbench unlocked multiple splicing targets, which we advanced internally or through partnerships. – Proceeds will support creating new technology for artificial intelligence-accelerated therapeutic development and advancing Wilson disease program into the clinic. In parallel, progress in deep neural networks are revolutionizing fields such as image recognition, natural language processing and, more broadly, AI. However, in many cases, genomics data do not conform to the requirements posed by most DL architectures. Canadian US Family Offices & Angels It knows biology, from disease biomarkers all the way down to the level of DNA, RNA and the molecular machinery of the cell. Deep Genomics intends to use new funding to develop new treatments for rare genetic diseases, and to expand the company’s proprietary AI discovery platform to support the discovery and development of novel therapies for more common disorders. Deep learning models have an advantage over other genomics algorithms in the pre-processing steps that are usually manually curated, error-prone and time-consuming. Deep Genomics General Information Description. Deep Genomics Incorporated operates as a biotechnology company. Now, we’re creating and clinically evaluating new oligonucleotide therapies, designed up front to be effective and safe. We have found that the more we explore the universe of genetic therapies using AI, the more we discover dark regions that can be illuminated only with the development of new technology. Deep Genomics is a therapeutics company founded on computational biology and artificial intelligence. © 2021 DEEP GENOMICS. TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has … MaRS Centre, 661 University Avenue, Suite 480. 245 Fairview Mall Drive, Suite 500, Toronto, Ontario M2J 4T1 | tel: 647-872-6300. About Deep Genomic (Mining, Queen's), MBA (Finance, Toronto), is the Editor of Private Capital Journal, CanadaMetals.ca, TechWire.ca, and the former Editor of Canadian Private Equity. Learn about the latest developments at Deep Genomics, Revolutions in AI, biology and automation are enabling a new approach, “Deep Genomics, founded in 2015, is at the forefront of efforts by big companies, startups and ...”, “For the first time in history, our ability to collect data on our biology has outpaced our ability to...”, “The basic fact is no human or group of humans will ever understand how the genome works”, “The next blockbuster drug could be developed with help from machine learning techniques”. Tags medtronic google deepmind Enlitic. It knows biology, from disease biomarkers all the way down to the level of DNA, RNA and the molecular machinery of the cell. March 16, 2017. Advancements in genomic research such as high-throughput sequencing techniques have driven modern genomic studies into "big data" disciplines. Top Gene-Sequencing Stocks for 2019 These next-generation companies are working on game-changing ways to obtain and profit from genetic insight. We are looking for individuals who are inspired to join us in building a new kind of world-class genetic medicine company. Deep Genomics is based in Toronto and Boston. This financing will enable us to expand our AI technology in the pursuit of new therapeutic opportunities, to advance our Wilson program into the clinic, and to strategically partner assets emerging from our overflowing preclinical pipeline.” Deep Genomics, a leading artificial intelligence (AI) therapeutics company, has raised US $40 million in Series B round led by Future Ventures and with participation of Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures. Deep Genomics closed its US $13 million Series A in 2017 led by Khosla Ventures. Thermo Scientific™ TSX Series ultra-low freezers, high-performance refrigerators and freezers are designed with features that support sustainability objectives without compromising performance. Its software system, Saturn, is used to search across 69 billion molecules and pinpoint 1,000 compounds that can be used to alter the composition of cells. Everyone at Deep Genomics uses the platform to do their work, and everyone participates in improving the platform. photo credit: Deep Genomics. Think your company should be on this list? Toronto-Dominion Bank (TSX:TD)(NYSE:TD) is at the forefront of this evolution. This course explores the exciting intersection between these two advances. Canadian US Private Equity Firms, Private Capital Journal is a publication of CPE News, Canada’s trusted and unbiased all private capital and public news, © 2021 CPE News, a division of CPE Media Inc. All Rights Reserved. BioMarin Pharmaceutical Inc. "BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence." Please confirm your subscription. “The powerful application of AI at Deep Genomics has created a drug development platform that is rapidly producing high quality drug candidates,” said Dion Madsen, partner at the biotech VC firm Amplitude Ventures. This is a game changer. Deep Genomics uses AI to power every stage of drug development, from identifying therapeutic targets that were previously dismissed as being undruggable, to designing novel therapeutic candidates, to designing animal models. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the closing of its Series B round with $40 million in new investment. Sector/subsector: The course will provide an introduction to deep learning and overview the relevant background in genomics, high-throughput biotechnology, protein and drug/small molecule interactions, medical imaging and other clinical measurements focusing on the available data and their relevance. Our proprietary AI Workbench enables us to identify leads for over 50% of the novel targets we select, and to do so within 12 months. has joined the company as a Strategic Advisor. It's AI-based systems, datasets, processes and culture enable the intentional design of effective and highly safe genetic medicines with a speed and a success rate that far exceed what was previously possible. Everyone at Deep Genomics uses the platform to do their work, and everyone participates in improving the platform. Ted Liu, M.Sc. Revolutions in AI, biology and automation are enabling a new approach to medicine. “Therapeutically re-engineering the human genome is the final frontier,” said Brendan Frey, founder and CEO of Deep Genomics. Ted has been passionately tracking Canadian private capital industry since 1992, having most recently served as Research Director for The Canadian Venture Capital and Private Equity Association (CVCA). Deoxyribonucleic acid (DNA) is the chemical compound that contains the instructions needed to develop and direct the activities of nearly all living organisms. The future of drug development will rely on artificial intelligence, because biology is too complex for humans to understand. TORONTO – January 7, 2020. Canadian US Venture Capital Firms My partner Maryanna Saenko and I are excited to be joining them on a journey to modernize drug development by using AI to design and derisk drug development programs up front, instead of relying on trial-and-error experiments that are fraught with time delays and high cost.”. The company plans to advance two programs to IND in 2020 and obtain Phase 1/2 data for its Wilson disease candidate in 2021. Advances in AI and ML are reshaping healthcare. DeepGenetics is a Silicon Valley based company that has been delivering Bioinformatics and Genomics solutions to clients. The genetic analysis of complex traits does not escape the current excitement around artificial intelligence, including a renewed interest in “deep learning” (DL) techniques such as Multilayer Perceptrons (MLPs) and Convolutional Neural Networks (CNNs). Unconfirmed subscriptions will be removed within 24 hours. Deep Genomics taps into that 98.5 percent of the genome that hasn't been studied closely for mutations and looks for the disease consequences of any mutations it finds. Our AI platform rapidly directs us to the best drug candidates. Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the closing of its Series B round with $40 million in ne Data & News supplied by www.cloudquote.io Stock quotes … Toronto based Deep Genomics is developing a universe of individualized genetic medicines by creating AI systems that are used to accelerate all steps of drug discovery and development, including target discovery, lead optimization, toxicity assessment and innovative trial design. What is DNA? For more information, visit www.deepgenomics.com and follow us on Twitter at @deepgenomics. Tickers TC. However, the performance of DL for genomic prediction of complex human traits has not been comprehensively tested. “We are excited to support this leading precision medicine company by investing in their new approach to drug development.”. Deep Genomics is located in the heart of Toronto, the fastest growing tech hub in North America. Our AI platform rapidly directs us to the best drug candidates.